Against the difficult and trying backdrop of the pandemic, cancer investigators persisted, and for patients with lung cancer, that persistence paid off in spectacular ways. With several new FDA approved treatments, as well as 2 new targetable mutations in non-small cell lung cancer (NSCLC), 2020 was a banner year in the overall lung cancer space. ONCOLOGY® recently sat down with Jennifer W. Carlisle, MD, of Emory University's Winship Cancer Institute, to discuss the many advances made during the last year for patients with lung cancer along with her hopes for further significant milestones in the year to come.

ONCOLOGY® recently sat down with Hope S. Rugo, MD, FASCO professor of medicine and director of breast oncology and clinical trials at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, to discuss some of the data presented at this year's SABCS and their implications for the future treatment of patients with breast cancer.

The 17th annual meeting of the International Society of Gastrointestinal Oncology (ISGIO) was held as a 2-day virtual event on October 2-3, 2020. This multidisciplinary educational conference is dedicated to presenting and discussing some of the latest advances in the field of gastrointestinal cancer research. ONCOLOGY® sat down with the co-chairs of the conference, Tanios S. Bekaii-Saab, MD, section chief for Medical Oncology in the Department of Internal Medicine at Mayo Clinic in Phoenix, Arizona, and Daniel G. Haller, MD, professor of medicine emeritus, Abramson Cancer Center at the Perelman School of Medicine at the University of Pennsylvania, in Philadelphia, to discuss the abstracts that were presented.

SARCLISA is an anti-CD38 therapy proven to deliver superior PFS (median PFS, 11.53 months with SARCLISA + Pd vs 6.47 months with Pd alone, HR=0.596, 95% CI: 0.44, 0.81, P=0.0010).SARCLISA also demonstrated a signifi cant increase in ORR (60.4% with SARCLISA + Pd [95% CI: 52.2%, 68.2%] vs 35.3% with Pd alone [95% CI: 27.8%, 43.4%], P<0.0001) 1 * Indication SARCLISA (isatuximab-irfc) is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Important Safety Information CONTRAINDICATIONSSARCLISA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients. WARNINGS AND PRECAUTIONS Infusion-Related ReactionsInfusion-related reactions (IRRs) have been observed in 39% of patients treated with SARCLISA.All IRRs started during the fi rst SARCLISA infusion and resolved on the same day in 98% of the cases.The most common symptoms of an IRR included dyspnea, cough, chills, and nausea.The most common severe signs and symptoms included hypertension and dyspnea.

SARCLISA is an anti-CD38 therapy proven to deliver superior PFS (median PFS, 11.53 months with SARCLISA + Pd vs 6.47 months with Pd alone, HR=0.596, 95% CI: 0.44, 0.81, P=0.0010).SARCLISA also demonstrated a signifi cant increase in ORR (60.4% with SARCLISA + Pd [95% CI: 52.2%, 68.2%] vs 35.3% with Pd alone [95% CI: 27.8%, 43.4%], P<0.0001) 1 * Indication SARCLISA (isatuximab-irfc) is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Important Safety Information CONTRAINDICATIONSSARCLISA is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients. WARNINGS AND PRECAUTIONS Infusion-Related ReactionsInfusion-related reactions (IRRs) have been observed in 39% of patients treated with SARCLISA.All IRRs started during the fi rst SARCLISA infusion and resolved on the same day in 98% of the cases.The most common symptoms of an IRR included dyspnea, cough, chills, and nausea.The most common severe signs and symptoms included hypertension and dyspnea.